News | January 21, 2026
Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Improvements were also seen in complete response rates, duration of response, and time to next treatment
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Over 8.8?million Indians aged 60 and above currently live with dementia,
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Subscribe To Our Newsletter & Stay Updated
